Építés alatt – nem éles oldal
Belépés
Befejeződött2. fázis

A Study for Evaluating Safety & Efficacy of Topical Roflumilast 0.3% Foam in Hidradenitis Suppurativa

A legfontosabb adatok

Ki végzi
Tulane University
Hol
Covington és New Orleans (Egyesült Államok)Mind a 4 helyszín megnézése
Azonosító
Állapot
Befejeződött
Fázis
2. fázis
Résztvevők
10 fő vett részt
Kezdés
2025. szept. 25.
Befejezés
2026. szept. 28.
A vizsgálat típusa
Beavatkozással járó
A vizsgált kezelések
  • Topical roflumilast 0.3% foam
A regiszteradat frissítve
2026. október 9.

Ki vehet részt

Életkor
18 év – 90 év
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 18 feltétel megnézéseKevesebb

Ki vehet részt

  • Must understand the risks and the benefits/purpose of the study and provide signed and dated informed consent
  • Must be 18 years at time of signing informed consent form
  • Willing to participate in all required evaluations and procedures in the study including the ability to apply topical medication without difficulty
  • Patients must have a diagnosis of HS based upon the clinical criteria of a history of more than or equal 5 typical lesions (erythematous papules, nodules, or abscesses) in flexural sites with a recurring nature over time
  • Patients must be candidate for topical therapy defined by active Hurley stage I or Hurley stage II/III with active disease after an adequate trial of systemic antibiotics/hormonal/immunomodulatory or biologic therapy
  • Patient is required to be on stable dose of concomitant therapy for at least 3 months before enrollment and throughout the study period
  • Females of childbearing potential must have a negative urine pregnancy test at baseline visit and be on adequate contraception throughout the study time

Ki nem vehet részt

  • Concomitant use of topical antibiotics, topical corticosteroids, resorcinol, benzoyl peroxide, vitamin D analogs, Hibiclens wash (except for emollients) within 1 week of enrollment
  • Increasing or changing dosing for concurrent therapy agents within 90 days before study day 0 and during the study period
  • Prior major surgery or major life-threatening medical illness within 2 weeks
  • Any severe systemic illness requiring Intravenous (IV) antibiotics within the two weeks prior to initiation of the study drug
  • Active substance abuse or a history of substance abuse within 6 months prior to screening
  • Use of any investigational drug within 4 weeks prior to randomization, or 5 pharmacokinetic/pharmacodynamic half-lives, if known (whichever is longer)
  • History of any clinically significant (as determined by the investigator) cardiac, endocrinologic, pulmonary, neurologic, psychiatric, hepatic, renal, hematologic, immunologic, or other major uncontrolled disease
  • Active hepatitis B or C infection with detectible viral nucleic acid in the blood or known Human Immunodeficiency Virus (HIV) positivity
  • Patients with known active malignancy
  • Any condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study
  • Pregnant or breastfeeding

Helyszínek itt: Egyesült Államok

  • Lakeview HospitalCovington, Egyesült Államok
  • Lakeside HospitalNew Orleans, Egyesült Államok
  • LCMC Multi-speciality ClinicNew Orleans, Egyesült Államok
  • University Medical CenterNew Orleans, Egyesült Államok

A vizsgálatról

Mit akar kideríteni a vizsgálat

This is a phase 2a, open label study.

A teljes eredeti leírásKevesebb

As psoriasis and Hidradenitis Suppurativa (HS) share multiple inflammatory pathways, the investigators hypothesize that the use of topical roflumilast 0.3% foam is a safe and efficacious option as a monotherapy for patients with mild disease and as add-on therapy for maintenance and flares in patients with moderate to severe disease. The study will include correlative analysis to study gene expression profiling before and after therapy.

A vizsgálat csoportja

  • HS patients armA vizsgált kezelés

    Patients must have a diagnosis of HS based upon the clinical criteria of a history of more or equal than 5 typical lesions (erythematous papules, nodules, or abscesses) in flexural sites with a recurring nature over time. Patients must be candidate for topical therapy defined by active Hurley stage I or Hurley stage II/III with active disease after an adequate trial of systemic antibiotics/hormonal/immunomodulatory or biologic therapy.

    Kezelés: Topical roflumilast 0.3% foam

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
An Open Label Study for Evaluating Safety & Efficacy of Topical Roflumilast 0.3% Foam as a Mono or add-on Therapy in the Treatment of Hidradenitis Suppurativa With Correlative Analysis.
A regiszteradat frissítve
2026. október 9.